MRNS - Marinus Pharmaceuticals Inc Stock Price, Fair Value and News

$0.23-0.01 (-4.17%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

MRNS Price Action

Last 7 days

-11.5%

Last 30 days

-25.8%

Last 90 days

-86.1%

Trailing 12 Months

-97.6%

MRNS RSI Chart

MRNS Valuation

Market Cap

12.7M

Price/Earnings (Trailing)

-0.09

Price/Sales (Trailing)

0.4

EV/EBITDA

0.25

Price/Free Cashflow

-0.15

MRNS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MRNS Fundamentals

MRNS Revenue

Revenue (TTM)

31.5M

Rev. Growth (Yr)

16.39%

Rev. Growth (Qtr)

6.02%

MRNS Earnings

Earnings (TTM)

-140.5M

Earnings Growth (Yr)

26.53%

Earnings Growth (Qtr)

32.39%

MRNS Profitability

EBT Margin

-428.38%

Return on Equity

210.5%

Return on Assets

-220.81%

Free Cashflow Yield

-649.97%

MRNS Investor Care

Shares Dilution (1Y)

1.12%

Diluted EPS (TTM)

-2.47

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	28.3M	30.3M	31.5M	0
2023	21.7M	26.0M	31.0M	31.0M
2022	27.7M	27.6M	19.8M	25.5M
2021	3.6M	5.4M	15.4M	15.3M
2020	0	0	276.5K	1.8M
2016	72.0K	91.0K	112.0K	127.5K
2015	23.5K	37.5K	48.5K	64.0K
2014	38.6K	30.3K	21.9K	13.5K
2013	0	0	0	47.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

CEO	Dr. Scott N. Braunstein M.D.
WEBSITE	https://marinuspharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	151

Marinus Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Marinus Pharmaceuticals Inc? What does MRNS stand for in stocks?

MRNS is the stock ticker symbol of Marinus Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Marinus Pharmaceuticals Inc (MRNS)?

As of Fri Dec 20 2024, market cap of Marinus Pharmaceuticals Inc is 12.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRNS stock?

You can check MRNS's fair value in chart for subscribers.

Is Marinus Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether MRNS is over valued or under valued. Whether Marinus Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Marinus Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRNS.

What is Marinus Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, MRNS's PE ratio (Price to Earnings) is -0.09 and Price to Sales (PS) ratio is 0.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRNS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Marinus Pharmaceuticals Inc's stock?

In the past 10 years, Marinus Pharmaceuticals Inc has provided -0.391 (multiply by 100 for percentage) rate of return.